Literature DB >> 8455931

Cyclins D1 and D2 are differentially expressed in human B-lymphoid cell lines.

I Palmero1, A Holder, A J Sinclair, C Dickson, G Peters.   

Abstract

The cyclin D1 gene can be transcriptionally activated in lymphoid tumours as a result of chromosomal rearrangements but is normally silent in B and T lymphocytes. By isolating cyclin D1-related cDNAs from a B-lymphoid cell line, we identified clones that contain the coding sequences of human cyclin D2. The predicted 289 amino acid protein shares 63% identity with human cyclin D1. Although cyclin D2 transcripts were detected in many lymphoid cell lines, it was not ubiquitously expressed and there was no apparent correlation with cyclin D1 levels. For example, two B-cell leukaemia lines, JVM-2 and Karpas 620, both of which have 11q13 translocations and express cyclin D1, contained markedly different amounts of cyclin D2. An obvious distinction between these cells is that the JVM-2 line, which expresses high levels of cyclin D2, was immortalized by Epstein-Barr virus (EBV). We subsequently found that cyclin D2 is consistently expressed in group III Burkitt's lymphoma (BL) and in lymphoblastoid cell lines immortalized by EBV, but not in group I BLs, in which expression of the EBV genome is more restricted. The data imply that the D-type cyclins may have non-overlapping functions at specific stages of lymphocyte differentiation and that the expression of cyclin D2 may be influenced, directly or indirectly, by EBV.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8455931

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells.

Authors:  M Meyyappan; H Wong; C Hull; K T Riabowol
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

2.  Expression of cyclin D2 in Epstein-Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene.

Authors:  A J Sinclair; I Palmero; A Holder; G Peters; P J Farrell
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

3.  Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity.

Authors:  W Chen; N R Cooper
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

4.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).

Authors:  J J Russo; R A Bohenzky; M C Chien; J Chen; M Yan; D Maddalena; J P Parry; D Peruzzi; I S Edelman; Y Chang; P S Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

5.  Differential tumorigenicity between Epstein-Barr virus genome-positive and genome-negative cell lines with t(11;14)(q13;q32) derived from mantle cell lymphoma.

Authors:  M Daibata; I Kubonishi; I Miyoshi
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

6.  Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells.

Authors:  Seiji Maruo; Yi Wu; Satoko Ishikawa; Teru Kanda; Dai Iwakiri; Kenzo Takada
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-11       Impact factor: 11.205

7.  Transforming growth factor beta effects on expression of G1 cyclins and cyclin-dependent protein kinases.

Authors:  Y Geng; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

8.  Immunohistochemistry of cyclin D3 in pulmonary carcinomas.

Authors:  H Usuda; T Saito; I Emura; M Naito
Journal:  Virchows Arch       Date:  1996-06       Impact factor: 4.064

Review 9.  Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis.

Authors:  Abhik Saha; Erle S Robertson
Journal:  Future Microbiol       Date:  2013-03       Impact factor: 3.165

10.  Identification of G1 kinase activity for cdk6, a novel cyclin D partner.

Authors:  M Meyerson; E Harlow
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.